Life Sciences Daily Summary
Life Sciences Daily Summary: What Happened on November 11, 2026
Beam’s sickle cell therapy meets its pivotal-trial goal
The day also brought FDA approvals for two drugs, a Phase 3 win in Sjögren’s disease and argenx’s proposed $1.15 billion acquisition.
Today in brief
Beam Therapeutics said risto-cel met its primary efficacy goal in a sickle cell trial, which required 12 months without severe pain crises.12 Amgen’s dazodalibep met the primary endpoint in a Phase 3 Sjögren’s disease trial, and Johnson & Johnson reported a Phase 3 win for Caplyta in bipolar mania.34
The FDA approved Merck KGaA’s Pimjetmi for some adults with tenosynovial giant cell tumor and Bayer’s Sunharbo to reduce recurrent stroke risk.567 Argenx agreed to acquire Unnatural Products for $550 million upfront, plus milestone payments that could lift the price to $1.15 billion.89
Beam’s risto-cel hits its sickle cell trial endpoint
Beam said risto-cel met the primary efficacy endpoint in BEACON, an open-label study of people with severe sickle cell disease.1 The endpoint required at least 12 consecutive months without severe vaso-occlusive crises, painful episodes caused by blocked blood flow.12
By an October 20 data cutoff, 39 adults and 10 adolescents had received treatment, and 31 participants had completed the follow-up required for the endpoint.1 Beam said the trial also met its primary safety and secondary efficacy endpoints.1 The company said it may file a biologics license application with the FDA as soon as the end of 2026 and plans to present detailed pivotal-trial data in 2027.1
Dazodalibep meets its Phase 3 endpoint in Sjögren’s disease
Both dazodalibep regimens reduced systemic disease activity more than placebo at week 48 in the 648-person OASIZ-301 trial.3 With dosing every four weeks, disease activity scores fell by 5.6 points, compared with 3.8 points on placebo.3
That regimen also improved patient-reported dryness and stimulated salivary flow compared with placebo.3 Adverse events reported more often with dazodalibep included infections, hypertension and infusion reactions, generally described as mild to moderate.3 Serious adverse events and treatment discontinuations were balanced between groups, and malignancy rates were low and similar.3
FDA clears Pimjetmi for certain people with joint tumors
The FDA approved Merck KGaA’s once-daily oral drug Pimjetmi for adults with symptomatic tenosynovial giant cell tumor when surgery could worsen function or cause serious complications.56 The rare tumor can cause pain and limit movement around affected joints.5
In the Phase 3 Maneuver trial, 56% of patients taking pimicotinib had an objective tumor response at week 25, compared with 3% on placebo.56 The trial also found improvements in range of motion, physical function and pain compared with placebo.10 Merck reported no evidence of liver toxicity in the pivotal trial.10
Sunharbo wins FDA approval to prevent another stroke
On November 9, the FDA approved Bayer’s asundexian, sold as Sunharbo, with antiplatelet therapy for adults after certain ischemic strokes or high-risk transient ischemic attacks.711 The approval makes it the first Factor XIa inhibitor approved worldwide, according to the cited account.712
In the Phase 3 Oceanic-stroke trial, adding asundexian reduced ischemic stroke by 26% compared with antiplatelet therapy alone, while major bleeding rates were similar to placebo.712 Bayer said the once-daily pill would launch in the United States in mid-November.11
FDA requires a potential rare-eye-risk warning on GLP-1 labels
On November 9, the FDA directed manufacturers of approved GLP-1 receptor agonists to add a warning about a possible increased risk of non-arteritic anterior ischemic optic neuropathy, a condition that can cause vision loss.1314 The agency advised patients and caregivers to contact a health professional promptly if symptoms arise, and people with a previous episode to discuss whether to continue treatment.13
An FDA meta-analysis identified 15 probable cases among trial participants, 10 in people taking a GLP-1 drug and five in placebo recipients.13 The agency said the combined evidence indicated a possible increased risk. A retrospective study found no statistically significant increase compared with SGLT-2 inhibitors, but did find an association compared with DPP-4 inhibitors.13
Argenx to buy Unnatural Products for up to $1.15 billion
Argenx agreed to acquire Unnatural Products for $550 million upfront, with up to $595 million more tied to development and regulatory milestones.8 The deal would give Argenx full ownership of the company, where it previously held a minority stake.8
Unnatural Products uses AI-assisted compound design, large-scale synthesis and screening to develop macrocyclic peptides.89 The companies expect the acquisition to close by year-end, subject to customary conditions. They expect the Santa Cruz site to become Argenx’s peptide-discovery hub.8
CVS plans to separate its retail pharmacies from health businesses
CVS Health plans to split into two publicly traded companies, separating its retail pharmacies from a health care business that would retain Aetna, Caremark, CVS Specialty, Oak Street Health and Signify Health.15 The company expects the separation in the first half of 2028, subject to conditions and final approvals.15
The proposed pharmacy company would operate about 9,000 retail locations, while Caremark and CVS Specialty would remain with Aetna in the other business.15 CVS said the split could give each company more strategic focus and allow the pharmacy business to pursue broader commercial partnerships.15
Tandem recalls Mobi insulin pump after false occlusion alarms
Tandem recalled its Mobi insulin pump after a problem with false occlusion alarms that could interrupt insulin delivery, according to the FDA recall database.16 Tandem reported 230 adverse events associated with the pump.16